Applied Therapeutics (APLT) Competitors

Prothena (NASDAQ:PRTA) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations, community ranking and media sentiment.

Does the media refer more to PRTA or APLT?

In the previous week, Prothena had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 9 mentions for Prothena and 8 mentions for Applied Therapeutics. Prothena's average media sentiment score of 0.51 beat Applied Therapeutics' score of 0.10 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Applied Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is PRTA or APLT more profitable?

Applied Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -98.86%. Prothena's return on equity of -24.03% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-98.86%	-24.03%	-20.12%
Applied Therapeutics	N/A	-260.75%	-76.04%

Does the MarketBeat Community favor PRTA or APLT?

Prothena received 528 more outperform votes than Applied Therapeutics when rated by MarketBeat users. Likewise, 70.51% of users gave Prothena an outperform vote while only 58.33% of users gave Applied Therapeutics an outperform vote.

Company	Underperform	Outperform
Prothena	Outperform Votes 605 70.51%	Underperform Votes 253 29.49%
Applied Therapeutics	Outperform Votes 77 58.33%	Underperform Votes 55 41.67%

Which has more risk and volatility, PRTA or APLT?

Prothena has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500.

Do institutionals and insiders believe in PRTA or APLT?

97.1% of Prothena shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 28.2% of Prothena shares are owned by company insiders. Comparatively, 8.6% of Applied Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Which has preferable valuation and earnings, PRTA or APLT?

Applied Therapeutics has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$91.37M	10.41	-$147.03M	-$2.48	-7.13
Applied Therapeutics	-$333K	-3,071.38	-$119.76M	-$1.61	-5.46

Do analysts prefer PRTA or APLT?

Prothena presently has a consensus target price of $61.86, indicating a potential upside of 249.87%. Applied Therapeutics has a consensus target price of $12.50, indicating a potential upside of 42.21%. Given Prothena's higher possible upside, equities analysts clearly believe Prothena is more favorable than Applied Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Applied Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17

Summary

Prothena beats Applied Therapeutics on 10 of the 18 factors compared between the two stocks.